Answers are grounded in this paper and cite their sources.
Idecabtagene vicleucel (ide-cel) the first FDA-approved gene therapy for relapsed refractory multiple myeloma (RRMM). However, its administration presents challenges in logistical management, selecting bridging therapy (BT), and customizing T-cell manufacturing, a complex process spanning several weeks [ 1 ]. In the KarMMa trial, BT was allowed but limited to specific prior drug classes (e.g., dexamethasone, cyclophosphamide (Cy), daratumumab, carfilzomib, bortezomib, or pomalidomide) [ 2 ]. This study delves into the impact of different BT on outcomes for RRMM patients undergoing standard of care (SOC) ide-cel treatment, aiming to clarify their role in CAR T therapy outcomes.
No takes yet. Share an insight, caveat, or question.
Afrough et al. (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: